Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Javed Butler

Advanced Heart Failure and Transplant Cardiology Jackson, MS Medical Doctor

NPI 1639100928 CMS profile 73926

2500 N State St, Jackson, MS 39216

Open in the dashboard

General payments

$4,094,606

1,409 records reported · program years 2019–2025

Research payments

$331,525

Paid to them · 79 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Javed Butler of Jackson, MS is reported in the CMS Open Payments database as having received $4,094,606 across 1,409 general payments and $331,525 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $567,484 175
2025 Research $57,270 42
2024 General $563,280 202
2024 Research $31,924 6
2023 General $625,332 229
2023 Research $19,844 8
2022 General $636,011 223
2022 Research $26,100 5
2021 General $738,063 163
2021 Research $50,966 6
2020 General $503,559 177
2020 Research $137,197 9
2019 General $460,877 240
2019 Research $8,225 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Javed Butler
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Javed Butler were reported at $567,484. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Javed Butler Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $460,877 $863 $224–$4,562 $163
2020 $503,559 $452 $122–$3,992 $114
2021 $738,063 $550 $159–$3,571 $132
2022 $636,011 $729 $221–$4,357 $149
2023 $625,332 $1,002 $309–$5,827 $160
2024 $563,280 $931 $273–$5,204 $164
2025 $567,484 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim International GmbH $736,968 150 payments
  2. Impulse Dynamics (USA) Inc. $594,375 65 payments
  3. Merck Sharp & Dohme Corporation $471,937 272 payments
  4. Vifor (International) Ltd. $363,090 42 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $205,234 117 payments
  6. AstraZeneca Pharmaceuticals LP $196,929 103 payments
  7. Boehringer Ingelheim RCV GmbH & Co KG $128,933 31 payments
  8. Novartis Pharmaceuticals Corporation $121,257 68 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $119,327 71 payments
  10. Anumana, Inc. $99,000 3 payments
  11. Other $1,057,555 487 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $2,757,070 438 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $861,933 264 payments
  3. Travel and Lodging $408,434 365 payments
  4. Honoraria $42,200 17 payments
  5. Food and Beverage $22,169 320 payments
  6. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $2,500 1 payment
  7. Education $300 4 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $791,738 191 payments
  2. OPTIMIZER Cardiovascular Device $390,902 37 payments
  3. OPTIMIZER Cardiovascular Device $390,902 37 payments
  4. VERQUVO $291,370 182 payments
  5. JARDIANCE Diabetes $220,621 69 payments
  6. Veltassa Potassium Binder $209,488 24 payments
  7. Optimizer Smart System $162,678 16 payments
  8. ENTRESTO $115,737 60 payments
  9. Veltassa Potassium Binder $91,000 1 payment
  10. FARXIGA $90,402 63 payments
  11. Other $740,195 403 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharma AG $113,850 1 payment
  2. Medtronic, Inc. $45,675 6 payments
  3. Novo Nordisk AS $41,356 11 payments
  4. Boehringer Ingelheim International GmbH $33,109 35 payments
  5. American Regent $25,270 3 payments
  6. Novartis Pharmaceuticals Corporation $20,755 4 payments
  7. Medtronic Vascular, Inc. $20,075 5 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $17,700 9 payments
  9. CVRx, Inc. $7,850 2 payments
  10. ZOLL Circulation Inc $4,635 2 payments

Records

1,488 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record